142 related articles for article (PubMed ID: 21585629)
1. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF
Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
[TBL] [Abstract][Full Text] [Related]
2. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
Kovarik JM; Hartmann S; Bartlett M; Riviere GJ; Neddermann D; Wang Y; Port A; Schmouder RL
Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
[TBL] [Abstract][Full Text] [Related]
3. A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
Kovarik JM; Riviere GJ; Neddermann D; Maton S; Hunt TL; Schmouder RL
J Clin Pharmacol; 2008 Mar; 48(3):303-10. PubMed ID: 18218783
[TBL] [Abstract][Full Text] [Related]
4. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Kahan BD; Karlix JL; Ferguson RM; Leichtman AB; Mulgaonkar S; Gonwa TA; Skerjanec A; Schmouder RL; Chodoff L
Transplantation; 2003 Oct; 76(7):1079-84. PubMed ID: 14557756
[TBL] [Abstract][Full Text] [Related]
6. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
Kovarik JM; Schmouder RL; Barilla D; Büche M; Rouilly M; Berthier S; Wang Y; Van Saders C; Mayer T; Gottlieb AB
Ann Pharmacother; 2004; 38(7-8):1153-8. PubMed ID: 15138297
[TBL] [Abstract][Full Text] [Related]
7. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
Kovarik JM; Schmouder R; Barilla D; Wang Y; Kraus G
Br J Clin Pharmacol; 2004 May; 57(5):586-91. PubMed ID: 15089811
[TBL] [Abstract][Full Text] [Related]
8. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.
Skerjanec A; Tedesco H; Neumayer HH; Cole E; Budde K; Hsu CH; Schmouder R
J Clin Pharmacol; 2005 Nov; 45(11):1268-78. PubMed ID: 16239360
[TBL] [Abstract][Full Text] [Related]
9. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
Kovarik JM; Lu M; Riviere GJ; Barbet I; Maton S; Goldwater DR; Schmouder RL
Eur J Clin Pharmacol; 2008 May; 64(5):457-63. PubMed ID: 18196225
[TBL] [Abstract][Full Text] [Related]
10. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
David OJ; Ocwieja M; Meiser K; Emotte C; Jakab A; Wemer J; den Daas I; Schmouder R
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):540-4. PubMed ID: 22735460
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of fingolimod phosphate in healthy participants.
Wu K; Mercier F; David OJ; Schmouder RL; Looby M
J Clin Pharmacol; 2012 Jul; 52(7):1054-68. PubMed ID: 22110161
[TBL] [Abstract][Full Text] [Related]
13. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.
Budde K; Schmouder RL; Brunkhorst R; Nashan B; Lücker PW; Mayer T; Choudhury S; Skerjanec A; Kraus G; Neumayer HH
J Am Soc Nephrol; 2002 Apr; 13(4):1073-1083. PubMed ID: 11912269
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
[TBL] [Abstract][Full Text] [Related]
15. Oral fingolimod (gilenya) for multiple sclerosis.
Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
[No Abstract] [Full Text] [Related]
16. Delayed fingolimod-associated asystole.
Espinosa PS; Berger JR
Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
18. Ethnic sensitivity study of fingolimod in white and Asian subjects.
Kovarik JM; Slade A; Voss B; Schmidli H; Riviere GJ; Picard F; Sugita Y; Kawai R; Mee-Lee D; Schmouder RL
Int J Clin Pharmacol Ther; 2007 Feb; 45(2):98-109. PubMed ID: 17323789
[TBL] [Abstract][Full Text] [Related]
19. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
20. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.
Schmouder R; Serra D; Wang Y; Kovarik JM; DiMarco J; Hunt TL; Bastien MC
J Clin Pharmacol; 2006 Aug; 46(8):895-904. PubMed ID: 16855074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]